Chemistry:Myocardial perfusion imaging

From HandWiki
Short description: Nuclear medicine imaging method
Myocardial perfusion imaging
Medical diagnostics
Nl mpi2.jpg
Myocardial perfusion scan with thallium-201 for the rest images (bottom rows) and Tc-Sestamibi for the stress images (top rows)
SynonymsMyocardial perfusion scintigraphy
ICD-10-PCSC22G
MeSHD055414
OPS-301 code3-704, 3-721
eMedicine2114292

Myocardial perfusion imaging or scanning (also referred to as MPI or MPS) is a nuclear medicine procedure that illustrates the function of the heart muscle (myocardium).[1]

It evaluates many heart conditions, such as coronary artery disease (CAD),[2] hypertrophic cardiomyopathy and heart wall motion abnormalities. It can also detect regions of myocardial infarction by showing areas of decreased resting perfusion. The function of the myocardium is also evaluated by calculating the left ventricular ejection fraction (LVEF) of the heart. This scan is done in conjunction with a cardiac stress test. The diagnostic information is generated by provoking controlled regional ischemia in the heart with variable perfusion.

Planar techniques, such as conventional scintigraphy, are rarely used. Rather, single-photon emission computed tomography (SPECT) is more common in the US. With multihead SPECT systems, imaging can often be completed in less than 10 minutes. With SPECT, inferior and posterior abnormalities and small areas of infarction can be identified, as well as the occluded blood vessels and the mass of infarcted and viable myocardium.[3] The usual isotopes for such studies are either thallium-201 or technetium-99m.

History

The history of nuclear cardiology began in 1927 when Dr. Herrmann Blumgart developed the first method for measuring cardiac strength by injecting subjects with a radioactive compound known as Radium C (214Bi).[4][5] The substance was injected into the venous system and travelled through the right heart into the lungs, then into the left heart and out into the arterial system where it was then detected through a Wilson chamber. The Wilson chamber represented a primitive scintillation counter which could measure radioactivity. Measured over time, this sequential acquisition of radioactivity produced what was known as "circulation time". The longer the "circulation time", the weaker the heart. Blumgart's emphasis was twofold. First, radioactive substances could be used to determine cardiac physiology (function) and should be done so with the least amount of radioactivity necessary to do so. Secondly, to accomplish this task, one needs to obtain multiple counts over time.[citation needed]

For decades no substantial work was done, until 1959. Dr. Richard Gorlin's work on "resting" studies of the heart and nitroglycerin emphasized several points.[6] First, like Blumgart, he emphasized that evaluation of cardiac function required multiple measurements of change over time and these measurements must be performed under same state conditions, without changing the function of the heart in between measurements. If one is to evaluate ischemia (reductions in coronary blood flow resulting from coronary artery disease) then individuals must be studied under "stress" conditions and comparisons require "stress-stress" comparisons. Similarly, if tissue damage (heart attack, myocardial infarction, cardiac stunning or hibernation) is to be determined, this is done under "resting" conditions. Rest-stress comparisons do not yield adequate determination of either ischemia or infarction. By 1963, Dr. William Bruce, aware of the tendency of people with coronary artery disease to experience angina (cardiac chest discomfort) during exercise, developed the first standardized method of "stressing" the heart, where serial measurements of changes in blood pressure, heart rate and electrocardiographic (ECG/EKG) changes could be measured under "stress-stress" conditions. By 1965 Dr. William Love demonstrated that the cumbersome cloud chamber could be replaced by a Geiger counter, which was more practical to use. However, Love had expressed the same concern as many of his colleagues, namely that there were no suitable radioisotopes available for human use in the clinical setting.[7]

Use of thallium-201

By the mid-1970s, scientists and clinicians alike began using thallium-201 as the radioisotope of choice for human studies.[8] Individuals could be placed on a treadmill and be "stressed" by the "Bruce protocol" and when near peak performance, could be injected with thallium-201. The isotope required exercise for an additional minute to enhance circulation of the isotope. Using nuclear cameras of the day and given the limitations of Tl-201, the first "stress" image could not be taken until 1 hour after "stress". In keeping with the concept of comparison images, the second "stress" image was taken 4 hours after "stress" and compared with the first. The movement of Tl-201 reflected differences in tissue delivery (blood flow) and function (mitochondrial activity). The relatively long half-life of Tl-201 (73 hours) forced doctors to use relatively small (74–111 MBq or 2–3 mCi) doses of Tl-201, albeit with relatively large dose exposure and tissue effects (20 mSv). The poor quality images resulted in the search for isotopes which would produce better results.[9]

The introduction of technetium-99m isotopes

By the late 1980s, two different compounds containing technetium-99m were introduced: teboroxime [10] and sestamibi. The utilization of Tc-99m would allow higher doses (up to 1,100 MBq or 30 mCi) due to the shorter physical (6 hours) half life of Tc-99m. This would result in more decay, more scintillation and more information for the nuclear cameras to measure and turn into better pictures for the clinician to interpret.[citation needed]

Major indications

  • Diagnosis of CAD and various cardiac abnormalities.
  • Identifying location and degree of CAD in patients with a history of CAD.
  • Prognosis of patients who are at risk of having a myocardial or coronary incident (i.e. myocardial infarction, myocardial ischemia, coronary aneurysm, wall motion abnormalities).
  • Assessment of viable myocardium in particular coronary artery territory following heart attacks to justify revascularization
  • Post intervention revascularization (coronary artery bypass graft, angioplasty) evaluation of heart.
  • Evaluation of shortness of breath of a possible cardiac origin.[11]

Radiation dose

From 1993 to 2001, myocardial perfusion scans in the US increased >6%/y with "no justification".[12] Myocardial perfusion imaging scans are "powerful predictors of future clinical events", and in theory may identify patients for whom aggressive therapies should improve outcome. But this is "only a hypothesis, not a proof".[12] However, several trials have indicated the high sensitivity (90%) of the test, regardless of tracer, outweighing any potential detrimental effect of the ionising radiation.[13][14] In the UK, NICE guidance recommends myocardial perfusion scans following myocardial infarction or reperfusion interventions.[15] The power of prognosis from a myocardial perfusion scan is excellent and has been well tested, and this is "perhaps the area of nuclear cardiology where the evidence is most strong".[13][16]

Many radionuclides used for myocardial perfusion imaging, including rubidium-82, technetium-99m and thallium-201 have similar typical effective doses (15-35 mSv).[17] The Cardiac PET tracer nitrogen-13 ammonia, though less widely available, may offer significantly reduced doses (2 mSv).[17][18][19][20] Stress-only protocols may also prove to be effective at reducing costs and patient exposure.[21]

References

  1. ↑ Myocardial+Perfusion+Imaging at the US National Library of Medicine Medical Subject Headings (MeSH)
  2. ↑ Lee, J. C.; West, M. J.; Khafagi, F. A. (2013). "Myocardial perfusion scans". Australian Family Physician 42 (8): 564–7. PMID 23971065. https://www.racgp.org.au/afp/2013/august/myocardial-perfusion-scans/. 
  3. ↑ Merck manuals > Radionuclide Imaging Last full review/revision May 2009 by Michael J. Shea, MD. Content last modified May 2009
  4. ↑ Blumgart HL, Yens OC. Studies on the velocity of blood flow: I. The method utilized. J Clin Investigation 1927;4:1-13.
  5. ↑ Love, William D. (1965). "Isotope Technics in Clinical Cardiology". Circulation 32 (2): 309–315. doi:10.1161/01.CIR.32.2.309. PMID 14340959. http://circ.ahajournals.org/content/32/2/309.full.pdf. Retrieved 27 April 2012. 
  6. ↑ Gorlin R, Brachfeld N, MacLeod C. and Bopp P. Effect of nitroglycerin on the coronary circulation in patients with coronary artery disease or increased left ventricular work. Circulation 1959;19:705-18.
  7. ↑ Love WD. (1965) Isotope Technics in Clinical Cardiology. Circulation 32:309-15.
  8. ↑ DePuey, E. Gordon; Garcia, Ernest V.; Berman, Daniel Sholom (2001) (in en). Cardiac SPECT Imaging. Lippincott Williams & Wilkins. p. 117. ISBN 9780781720076. https://books.google.com/books?id=CqQgnHrDxrUC&pg=PA117. 
  9. ↑ Strauss, H. William; Bailey, Dale (March 2009). "Resurrection of Thallium-201 for Myocardial Perfusion Imaging". JACC: Cardiovascular Imaging 2 (3): 283–285. doi:10.1016/j.jcmg.2009.01.002. PMID 19356572. 
  10. ↑ Bisi, G; Sciagrà, R; Santoro, GM; Cerisano, G; Vella, A; Zerauschek, F; Fazzini, PF (July 1992). "Myocardial scintigraphy with Tc-99m-teboroxime: its feasibility and the evaluation of its diagnostic reliability. A comparison with thallium-201 and coronary angiography". Giornale Italiano di Cardiologia 22 (7): 795–805. PMID 1473653. 
  11. ↑ Multimodality Writing Group for Stable Ischemic Heart Disease et al. (February 2014). "ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons.". Journal of Cardiac Failure 20 (2): 65–90. doi:10.1016/j.cardfail.2013.12.002. PMID 24556531. 
  12. ↑ 12.0 12.1 Lauer, Michael S. (27 August 2009). "Elements of Danger — The Case of Medical Imaging". New England Journal of Medicine 361 (9): 841–843. doi:10.1056/NEJMp0904735. PMID 19710480. 
  13. ↑ 13.0 13.1 Underwood, S. R.; Anagnostopoulos, C.; Cerqueira, M.; Ell, P. J.; Flint, E. J.; Harbinson, M.; Kelion, A. D.; Al-Mohammad, A. et al. (1 February 2004). "Myocardial perfusion scintigraphy: the evidence". European Journal of Nuclear Medicine and Molecular Imaging 31 (2): 261–291. doi:10.1007/s00259-003-1344-5. PMID 15129710. 
  14. ↑ Applegate, K. E.; Amis Jr, E. S.; Schauer, D. A. (3 December 2009). "Radiation Exposure from Medical Imaging Procedures". New England Journal of Medicine 361 (23): 2289–2292. doi:10.1056/NEJMc0909579. PMID 19955531. 
  15. ↑ "Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction". 26 November 2003. https://www.nice.org.uk/guidance/ta73/chapter/1-guidance. 
  16. ↑ Shaw, L (April 2004). "Prognostic value of gated myocardial perfusion SPECT". Journal of Nuclear Cardiology 11 (2): 171–185. doi:10.1016/j.nuclcard.2003.12.004. PMID 15052249. 
  17. ↑ 17.0 17.1 Berrington de Gonzalez, A.; Kim, K.-P.; Smith-Bindman, R.; McAreavey, D. (22 November 2010). "Myocardial Perfusion Scans: Projected Population Cancer Risks From Current Levels of Use in the United States". Circulation 122 (23): 2403–2410. doi:10.1161/CIRCULATIONAHA.110.941625. PMID 21098448. 
  18. ↑ "Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and use of sealed Radioactive Sources" (pdf). Public Health England. 22 February 2017. https://www.gov.uk/government/publications/arsac-notes-for-guidance. 
  19. ↑ A revised effective dose estimate for the PET perfusion tracer Rb-82, deKemp et al, J NUCL MED MEETING ABSTRACTS, 2008. 49(MeetingAbstracts_1): p. 183P-b-.
  20. ↑ Radiopharmaceuticals for nuclear cardiology: radiation dosimetry, uncertainties, and risk., Stabin et al, J Nucl Med, 2008. 49(9): p. 1555-63.
  21. ↑ Stress-only Nuclear Myocardial Perfusion Imaging[yes|permanent dead link|dead link}}], Heston TF, Internet Med J, accessed 17-Feb-2012.



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Myocardial_perfusion_imaging&oldid=3323920"